Roche's experimental oral drug for breast cancer giredestrant could enter a market worth at least 10 billion Swiss francs ...

Roche's CEO said on Wednesday that the Swiss drugmaker's oral drug candidate for breast cancer giredestrant could enter a ...

Roche Holding AG will add manufacturing capacity in China to serve the country’s growing market, making it the latest ...

A decade into reformulating Pfizer’s oral renal cell carcinoma drug Inlyta (axitinib) into a treatment that can be injected ...

In Boston, we remember his Red Sox career from 1971-78. Specifically, the 1975 season when Tiant had 18 wins and 18 complete ...

David Roche, strategist at Quantum Strategy, says the Federal Reserve's initial jumbo cut gives markets the wrong impression ...

Meanwhile, the acquisition of AntlerA, which Roche called a leader in Wnt signaling, gives the pharma ownership of a library ...

The agreement's goal is to bring a blood-based test to market to stratify patients with traumatic brain injuries.

Roche argued that its obesity medications would prove to have advantages over its rivals’ — and that the demand for weight ...

A new survey commissioned by Big Pharma Roche has found that half of those polled “have either limited or no awareness” of ...

Roche Holding AG has more than five medicines that it could combine with weight-loss drugs, Chief Executive Officer Thomas ...

Roche said on Monday that three early-stage obesity and diabetes drug candidates from its acquisition of Carmot Therapeutics ...